PrimeRFP SCOUT · Federal Contract Recompete Brief

W81XWH19C0193 — ANALGESIC KETAMINE-CLINICAL TRIAL

ANALGESIC KETAMINE-CLINICAL TRIAL is a federal NONE award for Department of Defense (DOD) held by EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.. Estimated value $26.9M ($-5,338,949.5 obligated). Current period of performance ends Nov 19, 2026. Last award drew 1 bidder.

$26.9M
Estimated Value
$-5,338,949.5
Obligated
Nov 19, 2026
PoP End / Expires
1
Bidders (last award)

Track this contract

Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

See related expiring contracts →

Analysis

Public

EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. holds $453.8M across 7 federal awards, concentrated at Department of Health and Human Services (HHS). The prior award was single-bid — competitive dynamics may favor a challenge. Set-aside status: NONE. Recompete timing centers on the Nov 19, 2026 PoP end — agencies typically plan 12–18 months ahead.

Contract facts

NONE
Contract numberW81XWH19C0193
AgencyDepartment of Defense (DOD)
IncumbentEMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.
UEICNPVCR8DK7M8
NAICS541715
PSCAN93
PoP end (current)Nov 19, 2026
Obligated$-5,338,949.5

Recompete timing

Public
Expiring in 94 days

Current PoP ends Nov 19, 2026 (94 days remaining). Agencies typically plan 12–18 months ahead — at 3.1 months out, that window is already open. The buying decision is likely already in motion.

Watch this contract — one email →

Incumbent footprint

Public record

EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.$453.8M obligated across 7 awards (firm-wide, all agencies).

Sole agency: Department of Health and Human Services (HHS)
Department of Health and Human Services (HHS)$459.1M · 100% of firm total
Open full company profile

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP

Track this contract

Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

See the recompete window for W81XWH19C0193
More in SCOUT
Track this contract →

Alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

Size up the competition →

See all live recompete landscapes — who else is expiring, and where the openings are.

Research the incumbent →

Open EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.’s federal contract profile — agency mix, recompete pipeline, and teaming relationships.

Frequently asked questions

What is contract W81XWH19C0193?

W81XWH19C0193 (ANALGESIC KETAMINE-CLINICAL TRIAL) is a Department of Defense (DOD) award with an estimated value of $26.9M, currently held by EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.. Figures are USASpending-sourced public-record facts normalized by PrimeRFP SCOUT.

Who is the incumbent on W81XWH19C0193?

EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. is the incumbent with $453.8M across 7 related awards in SCOUT’s public footprint. The current period of performance ends Nov 19, 2026.

When does W81XWH19C0193 come up for recompete?

SCOUT tracks a period-of-performance end of Nov 19, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows. Explore it live — $90 Pilot →

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/W81XWH19C0193